Table 5.
The situation of six clinical parameters of etanercept group and traditional medicine group
| Group (n=100) | Time | Morning stiffness time (minutes) | VAS | BASDAI | BASFI | ESR (mm/h) | CRP (mg/L) |
|---|---|---|---|---|---|---|---|
| Etanercept | 0 weeks | 31.2±8.4 | 6.5±2.9 | 55.08±24.4 | 55.7±24.9 | 50.2±17.8 | 42.5±15.6 |
| 12 weeks | 13.5±7.5a | 3.6±2.3a | 17.0±11.0a | 16.5±8.4a | 21.4±7.3a | 14.5±4.6a | |
| Difference | 17.7±10.7b | 2.9±3.6 | 38.1±26.5b | 39.1±26.3 | 28.8±18.8b | 28.0±17.1 | |
| Traditional Medicine | 0 week | 36.5±8.3 | 6.9±2.9 | 56±18.44 | 55.6±24.7 | 51.5±17.5 | 42.9±15.8 |
| 12 weeks | 22.4±7.6a | 4.2±2.0a | 26.3±11.2a | 22.6±9.2a | 29.4±7.7a | 19.2±4.6a | |
| Difference | 14.1±11.8b | 2.7±3.4 | 29.7±22.6b | 33.1±26.3 | 22.1±19.5b | 23.7±16.6 |
VAS, visual analog scale; BASDAI, bath ankylosing spondylitis disease activity index; BASFI, bath ankylosing spondylitis function index; ESR, erythrocyte sedimentation rate; CRP, C‐reactive protein.
a
Comparison between pre‐ and pro‐ treatmentshowed significant difference (P<.05).
b
Comparison between etanercept group and traditional medicine group showed significant difference (P<.05).